The analysis of our review supports the concept of the beneficence of SGLT-2 inhibitors in T2DM patients, as these drugs had shown a more remarkable improvement of glycemic index, weight control, blood pressure reduction, and, most of all, MACE, hospitalizations for heart failure, and cardiovascular mortalities. The gene discussed is SLC5A2; the disease is heart failure.